Paeoniflorin: a natural candidate for the treatment of metabolic diseases
Open Access
- 2 April 2026
- journal article
- review article
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Abstract
The global prevalence of metabolic diseases (MetDs) is rising annually and poses a major challenge to public health. Paeoniflorin(PF), a naturally occurrinKeywords
Funding Information
- National Natural Science Foundation of China (32371185)
- Shanghai Science and Technology Plan Project (23010504200)
- Shanghai Oriental Talents Program
- Key Lab of Exercise and Health Sciences of Ministry of Education (2025KF002)
- Shanghai Key Lab of Human Performance (11DZ2261100)
This publication has 182 references indexed in Scilit:
- Emerging Targets in Type 2 Diabetes and Diabetic ComplicationsAdvanced Science, 2021
- Paeoniflorin inhibited nod‐like receptor protein‐3 inflammasome and NF‐κB‐mediated inflammatory reactions in diabetic foot ulcer by inhibiting the chemokine receptor CXCR2Drug Development Research, 2020
- Paeoniflorin‐6′‐o‐benzene sulfonate (CP‐25) improves vasculitis through inhibiting IL‐17A/JAK/STAT3 signaling pathway in endothelial cells of HFD CIA ratsPhytotherapy Research, 2020
- Mechanisms and in vitro models of drug-induced cholestasisArchives of Toxicology, 2019
- Paeoniflorin attenuates oxidized low‐density lipoprotein‐induced apoptosis and adhesion molecule expression by autophagy enhancement in human umbilical vein endothelial cellsJournal of Cellular Biochemistry, 2018
- New therapeutic concepts in bile acid transport and signaling for management of cholestasisHepatology, 2017
- Paeoniflorin ameliorates ANIT‐induced cholestasis by activating Nrf2 through an PI3K/Akt‐dependent pathway in ratsPhytotherapy Research, 2015
- Inhibitory effect of paeoniflorin on the inflammatory vicious cycle between adipocytes and macrophagesJournal of Cellular Biochemistry, 2012
- Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in miceDiabetologia, 2010
- Peroxisome proliferator‐activated receptor (PPAR) modulators: Diabetes and beyond*Medicinal Research Reviews, 2001